S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
A gold storm is coming… (Ad)
Why a new Alzheimer's drug is having a slow US debut
Sri Lanka marks independence anniversary amid economic woes
A gold storm is coming… (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
A gold storm is coming… (Ad)
Why a new Alzheimer's drug is having a slow US debut
Sri Lanka marks independence anniversary amid economic woes
A gold storm is coming… (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
A gold storm is coming… (Ad)
Why a new Alzheimer's drug is having a slow US debut
Sri Lanka marks independence anniversary amid economic woes
A gold storm is coming… (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
A gold storm is coming… (Ad)
Why a new Alzheimer's drug is having a slow US debut
Sri Lanka marks independence anniversary amid economic woes
A gold storm is coming… (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
NASDAQ:EGRX

Eagle Pharmaceuticals - EGRX Stock Forecast, Price & News

$33.51
-0.58 (-1.70%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$33.33
$34.40
50-Day Range
$28.24
$36.32
52-Week Range
$24.35
$53.78
Volume
130,595 shs
Average Volume
139,612 shs
Market Capitalization
$436.30 million
P/E Ratio
17.45
Dividend Yield
N/A
Price Target
N/A

Eagle Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
8.56% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.29
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
9.62%
From $1.56 to $1.71 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

290th out of 1,028 stocks

Pharmaceutical Preparations Industry

133rd out of 501 stocks

EGRX stock logo

About Eagle Pharmaceuticals (NASDAQ:EGRX) Stock

Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. Its products include RYANODEX, BENDEKA and BELRAPZO. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.

Receive EGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EGRX Stock News Headlines

EGRX.P - | Stock Price & Latest News | Reuters
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Eagle Pharmaceuticals (NASDAQ:EGRX) Cut to "Hold" at StockNews.com
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Recap: Eagle Pharmaceuticals Q3 Earnings
Eagle Pharmaceuticals Reports Third Quarter 2022 Results
See More Headlines
Receive EGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EGRX Company Calendar

Last Earnings
11/07/2022
Today
2/05/2023
Next Earnings (Estimated)
3/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EGRX
Fax
N/A
Employees
102
Year Founded
N/A

Profitability

Net Income
$-8,630,000.00
Pretax Margin
16.55%

Debt

Sales & Book Value

Annual Sales
$171.55 million
Book Value
$13.66 per share

Miscellaneous

Free Float
9,345,000
Market Cap
$436.30 million
Optionable
Optionable
Beta
0.89

Key Executives

  • Scott L. Tarriff
    President, Chief Executive Officer & Director
  • Brian Cahill
    Chief Financial Officer
  • Ryan Debski
    Chief Compliance Officer & Executive VP
  • Debra M. Hussain
    Senior Vice President & Head-Commercial
  • Daniel O'Connor
    CSO & Head-Corporate Development













EGRX Stock - Frequently Asked Questions

How have EGRX shares performed in 2023?

Eagle Pharmaceuticals' stock was trading at $29.23 at the start of the year. Since then, EGRX shares have increased by 14.6% and is now trading at $33.51.
View the best growth stocks for 2023 here
.

When is Eagle Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 6th 2023.
View our EGRX earnings forecast
.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced its quarterly earnings data on Monday, November, 7th. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of $0.23 by $0.50. The specialty pharmaceutical company had revenue of $65.90 million for the quarter, compared to the consensus estimate of $59.37 million. Eagle Pharmaceuticals had a net margin of 8.35% and a trailing twelve-month return on equity of 11.55%.

What guidance has Eagle Pharmaceuticals issued on next quarter's earnings?

Eagle Pharmaceuticals updated its FY23 earnings guidance on Tuesday, January, 10th. The company provided EPS guidance of $4.20-4.53 for the period, compared to the consensus EPS estimate of $4.42.

What other stocks do shareholders of Eagle Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Radius Health (RDUS), bluebird bio (BLUE), Clovis Oncology (CLVS), GW Pharmaceuticals (GWPH) and Incyte (INCY).

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Smith Graham & Co. Investment Advisors LP (1.78%), Allspring Global Investments Holdings LLC (1.16%), Scout Investments Inc. (1.08%), Assenagon Asset Management S.A. (0.86%), Euclidean Technologies Management LLC (0.56%) and Exchange Traded Concepts LLC (0.26%).
View institutional ownership trends
.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eagle Pharmaceuticals' stock price today?

One share of EGRX stock can currently be purchased for approximately $33.51.

How much money does Eagle Pharmaceuticals make?

Eagle Pharmaceuticals (NASDAQ:EGRX) has a market capitalization of $436.17 million and generates $298.23 million in revenue each year. The specialty pharmaceutical company earns $-8,630,000.00 in net income (profit) each year or $1.92 on an earnings per share basis.

How many employees does Eagle Pharmaceuticals have?

The company employs 102 workers across the globe.

How can I contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The official website for the company is www.eagleus.com. The specialty pharmaceutical company can be reached via phone at (201) 326-5300 or via email at investors@eagleus.com.

This page (NASDAQ:EGRX) was last updated on 2/5/2023 by MarketBeat.com Staff